Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
AuthorsVan der Lely, A J
Hutson, R K
Trainer, Peter J
Besser, G M
Barkan, Ariel L
Vance, Mary Lee
Freda, P U
Stewart, P M
Friend, K E
Clemmons, David R
Cook, D M
Phillips, L S
Strasburger, Christian J
Zib, K A
Davis, R J
Scarlett, J A
Thorner, Michael O
AffiliationErasmus Medical Centre Rotterdam, 40 Dr Molewaterplein, 3015 GD, Rotterdam, Netherlands. email@example.com
MetadataShow full item record
AbstractBACKGROUND: Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days. METHODS: Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are excluded from the efficacy analysis. FINDINGS: Mean serum IGF-1 concentrations fell by at least 50%: 467 mg/L (SE 24), 526 mg/L (29), and 523 mg/L (40) in patients treated for 6, 12 and 18 months, respectively (p<0.001), whereas growth hormone increased by 12.5 mg/L (2.1), 12.5 mg/L (3.0), and 14.2 mg/L (5.7) (p<0.001). Of the patients treated for 12 months or more, 87 of 90 (97%) achieved a normal serum IGF-1 concentration. In patients withdrawn from pegvisomant (n=45), serum growth hormone concentrations were 8.0 mg/L (2.5) at baseline, rose to 15.2 mg/L (2.4) on drug, and fell back within 30 days of withdrawal to 8.3 mg/L (2.7). Antibodies to growth hormone were detected in 27 (16.9%) of patients, but no tachyphylaxis was seen. Serum insulin and glucose concentrations were significantly decreased (p<0.05). Two patients experienced progressive growth of their pituitary tumours, and two other patients had increased alanine and asparate aminotransferase concentrations requiring withdrawal from treatment. Mean pituitary tumour volume in 131 patients followed for a mean of 11.46 months (0.70) decreased by 0.033 cm(3) (0.057; p=0.353). INTERPRETATION: Pegvisomant is an effective medical treatment for acromegaly.
CitationLong-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. 2001, 358 (9295):1754-9 Lancet
- A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
- Authors: Ezzat S, Gaspo R, Serri O, Ur E, Chik CL
- Issue date: 2009 Dec 1
- [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
- Authors: Zgliczyński W, Zdunowski P
- Issue date: 2007 Sep-Oct
- The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
- Authors: Parkinson C, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton PE, Trainer PJ
- Issue date: 2003 Aug
- Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
- Authors: Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G
- Issue date: 2006 Mar
- Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
- Authors: Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ
- Issue date: 2003 Dec